AstraZeneca Pharma India Limited (ASTRAZEN) Price & Analysis

Compare

21 Followers

ASTRAZEN Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹6,222.35 - ₹10,653.05

Previous CloseN/A

Volume65.42K

Average Volume (3M)1.70K

Market Cap

₹219.79B

Enterprise Value₹210.15B

Total Cash (Recent Filing)₹4.97B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)189.9

Beta0.70

Next Earnings

Aug 14, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Jul 18, 2025

Dividend Yield0.37%

Share Statistics

EPS (TTM)23.30

Shares Outstanding25,000,000

10 Day Avg. Volume1,512

30 Day Avg. Volume1,695

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹9,605.00

Price Target Upside10.93% Upside

Rating ConsensusHold

Number of Analyst Covering1

AstraZeneca Pharma India Limited News

AstraZeneca Pharma India Confirms Regulatory Compliance

AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has shared an announcement. AstraZeneca Pharma India Limited has submitted a...

28d ago

AstraZeneca Pharma India Sets Record Date for Final Dividend

AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has issued an announcement. AstraZeneca Pharma India Limited has announced that...

1M ago

AstraZeneca Pharma India to Discontinue Imdur Production

AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has shared an update. AstraZeneca Pharma India Limited has announced it...

5M ago

AstraZeneca Pharma India Faces Draft Order on Transfer Pricing Issues

AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has provided an announcement. AstraZeneca Pharma India Limited has received a...

5M ago

ASTRAZEN FAQ

What was AstraZeneca Pharma India Limited’s price range in the past 12 months?

AstraZeneca Pharma India Limited lowest stock price was ₹6222.35 and its highest was ₹10653.05 in the past 12 months.

What is AstraZeneca Pharma India Limited’s market cap?

AstraZeneca Pharma India Limited’s market cap is ₹219.79B.

When is AstraZeneca Pharma India Limited’s upcoming earnings report date?

AstraZeneca Pharma India Limited’s upcoming earnings report date is Aug 14, 2025 which is tomorrow.

How were AstraZeneca Pharma India Limited’s earnings last quarter?

AstraZeneca Pharma India Limited released its earnings results on May 30, 2025. The company reported ₹23.3 earnings per share for the quarter, beating the consensus estimate of N/A by ₹23.3.

Is AstraZeneca Pharma India Limited overvalued?

According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca Pharma India Limited pay dividends?

AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.37%. See more information on AstraZeneca Pharma India Limited dividends here

What is AstraZeneca Pharma India Limited’s EPS estimate?

AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AstraZeneca Pharma India Limited have?

AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.

What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?

AstraZeneca Pharma India Limited reported an EPS of ₹23.3 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.584%.

Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?

Currently, no hedge funds are holding shares in IN:ASTRAZEN

Company Description

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

AstraZeneca Pharma India Limited (ASTRAZEN) Earnings & Revenues

Historic Earnings Reports

ASTRAZEN Stock 12 Month Forecast

Average Price Target

₹9,605.00

▲(10.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6665":"₹6,665","9606":"₹9,606","7400.25":"₹7,400.3","8135.5":"₹8,135.5","8870.75":"₹8,870.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6665,7400.25,8135.5,8870.75,9606],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8867.91,8924.60923076923,8981.308461538461,9038.007692307692,9094.706923076923,9151.406153846154,9208.105384615385,9264.804615384615,9321.503846153846,9378.203076923077,9434.902307692308,9491.601538461538,9548.30076923077,{"y":9605,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7040.96,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6666.64,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7710.97,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7580.77,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6689.76,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7181.83,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7202.86,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6683.54,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8489.51,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8635.96,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9283.89,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8867.91,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8867.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >